Macrophages_NNS
in_IN
human_JJ
atheroma_NN
contain_VBP
PPARgamma_NN
:_:
differentiation-dependent_JJ
peroxisomal_JJ
proliferator-activated_JJ
receptor_NN
gamma_NN
-LRB-_-LRB-
PPARgamma_NN
-RRB-_-RRB-
expression_NN
and_CC
reduction_NN
of_IN
MMP-9_NN
activity_NN
through_IN
PPARgamma_NN
activation_NN
in_IN
mononuclear_JJ
phagocytes_NNS
in_FW
vitro_FW
._.

Mononuclear_JJ
phagocytes_NNS
play_VBP
an_DT
important_JJ
role_NN
in_IN
atherosclerosis_NN
and_CC
its_PRP$
sequela_NN
plaque_NN
rupture_NN
in_IN
part_NN
by_IN
their_PRP$
secretion_NN
of_IN
matrix_NN
metalloproteinases_NNS
-LRB-_-LRB-
MMPs_NNS
-RRB-_-RRB-
,_,
including_VBG
MMP-9_NN
._.

Peroxisomal_JJ
proliferator-activated_JJ
receptor_NN
gamma_NN
-LRB-_-LRB-
PPARgamma_NN
-RRB-_-RRB-
,_,
a_DT
transcription_NN
factor_NN
in_IN
the_DT
nuclear_JJ
receptor_NN
superfamily_NN
,_,
regulates_VBZ
gene_NN
expression_NN
in_IN
response_NN
to_TO
various_JJ
activators_NNS
,_,
including_VBG
15-deoxy-delta12_NN
,14_CD
-_TO
prostaglandin_NN
J2_NN
and_CC
the_DT
antidiabetic_JJ
agent_NN
troglitazone_NN
._.

The_DT
role_NN
of_IN
PPARgamma_NN
in_IN
human_JJ
atherosclerosis_NN
is_VBZ
unexplored_JJ
._.

We_PRP
report_VBP
here_RB
that_IN
monocytes\/macrophages_NNS
in_IN
human_JJ
atherosclerotic_JJ
lesions_NNS
-LRB-_-LRB-
n_NN
=_JJ
12_CD
-RRB-_-RRB-
express_VBP
immunostainable_JJ
PPARgamma_NN
._.

Normal_JJ
artery_NN
specimens_NNS
-LRB-_-LRB-
n_NN
=_JJ
6_CD
-RRB-_-RRB-
reveal_VBP
minimal_JJ
immunoreactive_JJ
PPARgamma_NN
._.

Human_JJ
monocytes_NNS
and_CC
monocyte-derived_JJ
macrophages_NNS
cultured_VBN
for_IN
6_CD
days_NNS
in_IN
5_CD
%_NN
human_JJ
serum_NN
expressed_VBD
PPARgamma_NN
mRNA_NN
and_CC
protein_NN
by_IN
reverse_JJ
transcription-polymerase_NN
chain_NN
reaction_NN
and_CC
Western_NN
blotting_NN
,_,
respectively_RB
._.

In_IN
addition_NN
,_,
PPARgamma_NN
mRNA_NN
expression_NN
in_IN
U937_NN
cells_NNS
increased_VBD
during_IN
phorbol_NN
12-myristate_NN
13_CD
acetate-induced_JJ
differentiation_NN
._.

Stimulation_NN
of_IN
PPARgamma_NN
with_IN
troglitazone_NN
or_CC
15-deoxy-delta12_NN
,14_CD
-_TO
prostaglandin_NN
J2_NN
in_IN
human_JJ
monocyte-derived_JJ
macrophages_NNS
inhibited_VBD
MMP-9_NN
gelatinolytic_JJ
activity_NN
in_IN
a_DT
concentration-dependent_JJ
fashion_NN
as_IN
revealed_VBD
by_IN
zymography_NN
._.

This_DT
inhibition_NN
correlates_VBZ
with_IN
decreased_VBN
MMP-9_NN
secretion_NN
as_IN
determined_VBN
by_IN
Western_NN
blotting_NN
._.

Thus_RB
,_,
PPARgamma_NN
is_VBZ
present_JJ
in_IN
macrophages_NNS
in_IN
human_JJ
atherosclerotic_JJ
lesions_NNS
and_CC
may_MD
regulate_VB
expression_NN
and_CC
activity_NN
of_IN
MMP-9_NN
,_,
an_DT
enzyme_NN
implicated_VBN
in_IN
plaque_NN
rupture_NN
._.

PPARgamma_NN
is_VBZ
likely_JJ
to_TO
be_VB
an_DT
important_JJ
regulator_NN
of_IN
monocyte\/macrophage_NN
function_NN
with_IN
relevance_NN
for_IN
human_JJ
atherosclerotic_JJ
disease_NN
._.

